Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICI) have reshaped treatment paradigms of multiple solid organ malignancies. In genitourinary malignancies (GU), ICI provide significant clinical benefit and are approved for use in localized and metastatic renal cell carcinoma and urothelial carcinoma....

Descripción completa

Detalles Bibliográficos
Autores principales: Labadie, Brian W., Balar, Arjun V., Luke, Jason J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582522/
https://www.ncbi.nlm.nih.gov/pubmed/34771578
http://dx.doi.org/10.3390/cancers13215415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582522/
https://www.ncbi.nlm.nih.gov/pubmed/34771578
http://dx.doi.org/10.3390/cancers13215415

Ejemplares similares